Evidence map›Paper›PMID 42163550›Full record

ReviewCancer biology & medicine2026

Microbial reprogramming of immunogenic cell death: a new paradigm in tumor immunotherapy.

Yilin Li, Huiyue Zhang, Yun Feng, Kun Fang, Yue Wang, Yuhang Zhou, Tao Sun, Junnan Xu

Abstract readReview
In one paragraph

Review in Cancer biology & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yilin LiDepartment of Breast Medicine 1, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang 110042, China.
Huiyue ZhangDepartment of Breast Medicine 1, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang 110042, China.
Yun FengDepartment of Breast Medicine 1, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang 110042, China.
Kun FangDepartment of Pharmacology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang 110042, China.
Yue WangDepartment of Breast Medicine 1, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang 110042, China.
Yuhang ZhouDepartment of Breast Medicine 1, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang 110042, China.
Tao SunDepartment of Breast Medicine 1, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang 110042, China.ORCID 0000-0001-5931-386X
Junnan XuDepartment of Breast Medicine 1, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang 110042, China.ORCID 0000-0001-9044-8455

Funding

LiaoNing Revitalization Talents Program XLYC1907160, XJNational Natural Science Foundation of China 82373113, XJNatural Science Foundation of Liaoning Province 2025-MSLH-421, XJShenyang Breast Cancer Clinical Medical Research Center 2020-48-3-1, STShenyang Public Health R&D Special Project 22-321-31-04, ST
6 · The paper itself

Abstract

Immunogenic cell death (ICD), a special form of cell death, transforms "cold" tumors into "hot" tumors by fulfilling the following three key conditions: antigenicity; adjuvanticity; and a suitable tumor microenvironment (TME). Tumor cells release damage-associated molecular patterns (DAMPs) during ICD, thereby activating the dendritic-cytotoxic T cell axis to elicit systemic antitumor immune responses. However, drug resistance and immune-related adverse effects often limit traditional ICD inducers, including chemotherapy and radiotherapy. Notably, microbiota and microbial metabolites can trigger ICD in tumor cells, leading to the release of DAMPs, modulation of immune cell functions, and TME remodeling. This study comprehensively reviews the mechanisms underlying ICD regulation

Indexed as

Immunogenic Cell DeathImmunotherapyMicrobiotaNeoplasmsAnimalsHumansTumor Microenvironmentantitumor immune responsesdamage-associated molecular patternsImmunogenic cell deathmicrobiota and microbial metabolitestumor microenvironment

Identifiers

PMID42163550
PMCPMC13244315

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.